BACKGROUND: The focal adhesion kinase (FAK) is a non-receptor tyrosine kinase linked to tumor growth, invasion, and metastasis. FAK is overexpressed and associated with prognosis in many cancers, but its prognostic value in small-cell lung carcinoma (SCLC) is unknown and was the focus of this study. METHODS: Total FAK expression was analyzed via immunohistochemistry in tissue microarrays consisting of formalin-fixed, paraffin-embedded SCLC specimens from 85 patients. FAK staining scores were tested for correlations with pathological characteristics and clinical outcomes. Phospho-paxillin was also tested in 35 of the 85 specimens to evaluate whether FAK expression was associated with downstream signaling. RESULTS: Specific FAK expression was localized to the cytoplasm of 78/85 (92%) SCLCs. FAK expression was scored low in 11 (13%), moderate in 17 (20%), and high in 50 (59%) SCLCs. FAK staining scores treated as continuous variables did not correlate with SCLC disease stage, response to therapy, recurrence/progression-free survival, or overall survival. Moreover, total FAK expression did not correlate with phospho-paxillin Tyr(118) expression. CONCLUSIONS: Total FAK is strongly expressed in a majority of SCLC tumors. However, the expression evaluated via immunohistochemistry is not a prognostic factor in patients with SCLC.
BACKGROUND: The focal adhesion kinase (FAK) is a non-receptor tyrosine kinase linked to tumor growth, invasion, and metastasis. FAK is overexpressed and associated with prognosis in many cancers, but its prognostic value in small-cell lung carcinoma (SCLC) is unknown and was the focus of this study. METHODS: Total FAK expression was analyzed via immunohistochemistry in tissue microarrays consisting of formalin-fixed, paraffin-embedded SCLC specimens from 85 patients. FAK staining scores were tested for correlations with pathological characteristics and clinical outcomes. Phospho-paxillin was also tested in 35 of the 85 specimens to evaluate whether FAK expression was associated with downstream signaling. RESULTS: Specific FAK expression was localized to the cytoplasm of 78/85 (92%) SCLCs. FAK expression was scored low in 11 (13%), moderate in 17 (20%), and high in 50 (59%) SCLCs. FAK staining scores treated as continuous variables did not correlate with SCLC disease stage, response to therapy, recurrence/progression-free survival, or overall survival. Moreover, total FAK expression did not correlate with phospho-paxillinTyr(118) expression. CONCLUSIONS: Total FAK is strongly expressed in a majority of SCLC tumors. However, the expression evaluated via immunohistochemistry is not a prognostic factor in patients with SCLC.
Authors: Pierre P Massion; Wen-Lin Kuo; David Stokoe; Adam B Olshen; Patrick A Treseler; Koei Chin; Chira Chen; Daniel Polikoff; Ajay N Jain; Daniel Pinkel; Donna G Albertson; David M Jablons; Joe W Gray Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: M Ayaki; K Komatsu; M Mukai; K Murata; M Kameyama; S Ishiguro; J Miyoshi; M Tatsuta; H Nakamura Journal: Clin Cancer Res Date: 2001-10 Impact factor: 12.531
Authors: S Ocak; H Yamashita; A R Udyavar; A N Miller; A L Gonzalez; Y Zou; A Jiang; Y Yi; Y Shyr; L Estrada; V Quaranta; P P Massion Journal: Oncogene Date: 2010-08-30 Impact factor: 9.867
Authors: T Miyazaki; H Kato; M Nakajima; M Sohda; Y Fukai; N Masuda; R Manda; M Fukuchi; K Tsukada; H Kuwano Journal: Br J Cancer Date: 2003-07-07 Impact factor: 7.640
Authors: Grace K Dy; Lourdes Ylagan; Saraswati Pokharel; Austin Miller; Elizabeth Brese; Wiam Bshara; Carl Morrison; William G Cance; Vita M Golubovskaya Journal: J Thorac Oncol Date: 2014-09 Impact factor: 15.609
Authors: Hong-Fei Ji; Da Pang; Song-Bin Fu; Yan Jin; Lei Yao; Ji-Ping Qi; Jing Bai Journal: J Cancer Res Clin Oncol Date: 2012-11-11 Impact factor: 4.553
Authors: Fredrick T Harris; S M Jamshedur Rahman; Mohamed Hassanein; Jun Qian; Megan D Hoeksema; Heidi Chen; Rosana Eisenberg; Pierre Chaurand; Richard M Caprioli; Masakazu Shiota; Pierre P Massion Journal: Cancer Prev Res (Phila) Date: 2014-05-12
Authors: Frank Aboubakar Nana; Marylène Lecocq; Maha Zohra Ladjemi; Bruno Detry; Sébastien Dupasquier; Olivier Feron; Pierre P Massion; Yves Sibille; Charles Pilette; Sebahat Ocak Journal: Mol Cancer Ther Date: 2018-10-23 Impact factor: 6.261
Authors: Jonathan M Lehman; Megan D Hoeksema; Jeremy Staub; Jun Qian; Bradford Harris; J Clay Callison; Jennifer Miao; Chanjuan Shi; Rosana Eisenberg; Heidi Chen; Sheau-Chiann Chen; Pierre P Massion Journal: Int J Cancer Date: 2018-10-09 Impact factor: 7.396
Authors: Yo Na Kim; Ji Eun Choi; Jun Sang Bae; Kyu Yun Jang; Myoung Ja Chung; Woo Sung Moon; Myoung Jae Kang; Dong Geun Lee; Ho Sung Park Journal: Korean J Pathol Date: 2012-10-25